Pavel Hamet
From Wikipedia, the free encyclopedia
Pavel Hamet is a doctor, researcher, editor, academic administrator and teacher in Quebec, Canada.
Working in the medical field, he is the Canada Research Chair in Predictive Genomics of hypertension and cardiovascular diseases. He is Professor of Medicine at the University of Montreal, Adjunct Professor of Experimental Medicine at McGill University, and visiting professor at the First Faculty of Medicine at Charles University, Prague, Czech Republic. He is currently Chief of Gene Medicine and member of the Endocrinology Services at the University of Montreal's Research Centre (CRCHUM).[1] He was designated president of the International Society of Pathophysiology (ISP) from 2010 to 2014. Associated editor of the Journal of Hypertension,[2] he is also a member of the Commission de l'éthique en science et en technologie of the Quebec government and president, chief of the scientific direction of Medpharmgene.[3] compagny.
Born in Czech Republic (or Protectorate of Bohemia and Moravia), Pavel Hamet received his Doctorate in medicine in 1967 from Charles University, a Ph.D. in Experimental Medicine from McGill University in 1972, and a CSPQ in Endocrinology from Université de Montréal in 1974. He then completed two years of postdoctoral training at Vanderbilt University in the US after which he started his career as a microbiologist. In 1966, he had the opportunity to visit Montreal during a contest organized by the International Federation of Medical Students' Association (IFMSA).[4] In 1967, he finished a PhD in medicine at Charles University, the same year he established in Quebec.
Once in Montreal, he met with Jacques Genest who offered him a scholarship at the Institut de recherches cliniques de Montréal (IRCM) affiliated with the University of Montreal. He then founded and directed the University of Montreal's Research Centre (CRCHUM) from 1996 to 2006.[5] From 2014, Hamet led a public-private $18.4 million project for Optimization of personalized therapeutic approaches in primary care entitled Optithera.[6]
